Beam Therapeutics (BEAM) Revenue (2019 - 2026)
Beam Therapeutics (BEAM) posted quarterly Revenue of $31.7 million for Q1 2026, up 324.87% year-over-year from $7.5 million in Q1 2025, and down 72.19% quarter-over-quarter from $114.1 million in Q4 2025.
Beam Therapeutics (BEAM) Revenue (2019 - 2026) Analysis & Trends
Beam Therapeutics (BEAM) has reported Revenue for 8 consecutive years, with $31.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Revenue rose 324.87% year-over-year to $31.7 million; the TTM figure through Mar 2026 stood at $164.0 million (up 157.97% YoY), while the FY2025 annual figure was $139.7 million, up 120.01% from the prior year.
- Revenue retreated to $31.7 million in Q1 2026 per BEAM's latest filing, from $114.1 million in the prior quarter.
- Across five years, Revenue topped out at $316.2 million in Q4 2023 and bottomed at $7.4 million in Q1 2024.
- Historically, Revenue has averaged $39.6 million across 5 years, with a median of $16.7 million in 2022.
- Annual changes were most pronounced in 2022 — Revenue soared 277433.33% — and 2024, when it slumped 90.49%.
- Beam Therapeutics' Revenue stood at $20.0 million in 2022, then surged by 1478.04% to $316.2 million in 2023, then plunged by 90.49% to $30.1 million in 2024, then soared by 279.52% to $114.1 million in 2025, then plunged by 72.19% to $31.7 million in 2026.
- Business Quant data shows BEAM's Revenue at $31.7 million in Q1 2026, $114.1 million in Q4 2025, and $9.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Beam Therapeutics | 2.76 Bn | 2.76 Bn | - | 490,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 490,000.00 |
| Mar 31, 2026 | 31.74 Mn |
| Dec 31, 2025 | 114.11 Mn |
| Sep 30, 2025 | 9.70 Mn |
| Jun 30, 2025 | 8.47 Mn |
| Mar 31, 2025 | 7.47 Mn |
| Dec 31, 2024 | 30.07 Mn |
| Sep 30, 2024 | 14.27 Mn |
| Jun 30, 2024 | 11.77 Mn |
| Mar 31, 2024 | 7.41 Mn |
| Dec 31, 2023 | 316.19 Mn |
| Sep 30, 2023 | 17.19 Mn |
| Jun 30, 2023 | 20.12 Mn |
| Mar 31, 2023 | 24.21 Mn |
| Dec 31, 2022 | 20.04 Mn |
| Sep 30, 2022 | 15.80 Mn |
| Jun 30, 2022 | 16.65 Mn |
| Mar 31, 2022 | 8.43 Mn |
| Dec 31, 2021 | 51.07 Mn |
| Sep 30, 2021 | 763,000.00 |